3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
22
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Sarcoma
10
Lung Neoplasms
9
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
7
Stomach Neoplasms
7
Pheochromocytoma
7
Paraganglioma
7
Head and Neck Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
7
Thyroid Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Diseases
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Prostatic Neoplasms
4
Neuroblastoma
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Lung Diseases
4
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Tertiary Lymphoid Structures
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled